GranuFlo® Lawsuits Consolidated in Massachusetts Federal Court
On March 29, 2013, the Judicial Panel on Multidistrict Litigation (JPML) announced that all NaturaLyte® and GranuFlo® federal lawsuits will be consolidated for pre-trial proceedings in the Northern District of Massachusetts.
Fresenius Medical Care, the manufacturer of NaturaLyte® and GranuFlo®, began selling the dialysates in 2003, when they first received FDA approval. Both are engineered to filter toxins from the blood during hemodialysis. Fresenius currently faces hundreds of claims from dialysis patients alleging serious injuries, including heart attacks, strokes, and even death. These lawsuits allege that NaturaLyte® and GranuFlo® contain dangerously high levels of bicarbonate, which can lead to heart attacks, stroke, and death. In fact, according to a report, Fresenius staff has determined individuals with high levels of bicarbonate in the blood are six times more likely to suffer adverse health effects.
If you or a loved one has experienced adverse health effects from GranuFlo®, contact the experienced pharmaceutical attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297. The firm represents plaintiffs nationwide in pharmaceutical litigation, as well as litigation involving other defective products. We will confidentially evaluate your case for free and without any obligation.
Legal Disclaimer: The choice of a lawyer is an important decision and should not be based solely on advertisements.